Gallagher, MJ;
Hogg, FRA;
Kearney, S;
Kopp, MA;
Blex, C;
Serdani, L;
Sherwood, O;
Schwab, JM;
Zoumprouli, A;
Papadopoulos, MC;
et al.
Gallagher, MJ; Hogg, FRA; Kearney, S; Kopp, MA; Blex, C; Serdani, L; Sherwood, O; Schwab, JM; Zoumprouli, A; Papadopoulos, MC; Saadoun, S
(2020)
Effects of local hypothermia-rewarming on physiology, metabolism and inflammation of acutely injured human spinal cord.
Sci Rep, 10 (1).
p. 8125.
ISSN 2045-2322
https://doi.org/10.1038/s41598-020-64944-y
SGUL Authors: Papadopoulos, Marios Saadoun, Samira
Abstract
In five patients with acute, severe thoracic traumatic spinal cord injuries (TSCIs), American spinal injuries association Impairment Scale (AIS) grades A-C, we induced cord hypothermia (33 °C) then rewarming (37 °C). A pressure probe and a microdialysis catheter were placed intradurally at the injury site to monitor intraspinal pressure (ISP), spinal cord perfusion pressure (SCPP), tissue metabolism and inflammation. Cord hypothermia-rewarming, applied to awake patients, did not cause discomfort or neurological deterioration. Cooling did not affect cord physiology (ISP, SCPP), but markedly altered cord metabolism (increased glucose, lactate, lactate/pyruvate ratio (LPR), glutamate; decreased glycerol) and markedly reduced cord inflammation (reduced IL1β, IL8, MCP, MIP1α, MIP1β). Compared with pre-cooling baseline, rewarming was associated with significantly worse cord physiology (increased ICP, decreased SCPP), cord metabolism (increased lactate, LPR; decreased glucose, glycerol) and cord inflammation (increased IL1β, IL8, IL4, IL10, MCP, MIP1α). The study was terminated because three patients developed delayed wound infections. At 18-months, two patients improved and three stayed the same. We conclude that, after TSCI, hypothermia is potentially beneficial by reducing cord inflammation, though after rewarming these benefits are lost due to increases in cord swelling, ischemia and inflammation. We thus urge caution when using hypothermia-rewarming therapeutically in TSCI.
Item Type: |
Article
|
Additional Information: |
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2020 |
SGUL Research Institute / Research Centre: |
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) |
Journal or Publication Title: |
Sci Rep |
ISSN: |
2045-2322 |
Language: |
eng |
Dates: |
Date | Event |
---|
15 May 2020 | Published | 21 April 2020 | Accepted |
|
PubMed ID: |
32415143 |
|
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/111960 |
Publisher's version: |
https://doi.org/10.1038/s41598-020-64944-y |
Statistics
Item downloaded times since 20 May 2020.
Actions (login required)
|
Edit Item |